Business Context and Reporting Period
Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2016
Event: Announcement of a partial settlement with Actavis regarding ongoing patent litigation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event and does not contain financial statement data.
Material Changes
Legal Settlement: On May 10, 2016, the Company entered into a partial settlement with Actavis concerning ongoing patent litigation. The filing incorporates a press release detailing this event by reference.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for details on the settlement but does not include specific management commentary, future guidance, or risk factors within the body of this 8-K text.
Contingencies: The partial settlement indicates a resolution of a portion of the ongoing patent litigation contingency with Actavis.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific financial terms of the partial settlement with Actavis.
- Verify the remaining scope of the patent litigation with Actavis following this partial settlement.
- Check subsequent filings for any impact of this settlement on the Company's cash flow or legal reserves.